Navigation Links
Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Date:7/2/2012

CRANBURY, N.J., July 2, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock.  Funds under the management of QVT Financial LP have agreed to pay $0.50 for each share of common stock and $0.49 for each Series A warrant and each Series B warrant, resulting in gross proceeds to Palatin of $35,000,000, with net proceeds, after deducting estimated offering expenses, of approximately $34,500,000.

The private placement is expected to close on or about July 5, 2012, subject to customary closing conditions.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.

Both Series A and Series B warrants are exercisable at an initial exercise price of $0.01 per share.  The Series A warrants are exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance.  The Series B warrants are also exercisable immediately upon issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the tenth anniversary of the date of the increase in the number of authorized shares.  Both the Series A warrants and the Series B warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of Palatin's shares of common stock following such exercise.
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
9. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
10. Animal Biotechnology - Technologies, Markets and Companies
11. Gene Therapy - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 21, 2015 Tunnell Consulting, ... firm as senior statistician and Principal, a position to ... in the management and analysis of complex and large ... industries. , “We’re delighted to have Julia join the ... analytics,” said Dr. Philippe Cini, Group Vice President and ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... - Conference Call Today at 5:00 p.m. Eastern Time ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... financial results,for the first quarter ended March 31, 2008., ... in moving our,clinical trials forward and generating data to ...
... of 2007 -, - Tests Delivered Grew 68 Percent Compared ... - Conference Call Today ... Genomic Health,Inc. (Nasdaq: GHDX ) today reported financial results and business ... $23.4 million in the first quarter of 2008,compared to $14.1 million in ...
... Revell, world-renowned Pfizer Enterprise 2.0 expert, to deliver ... ... HERSHEY, Pa., May 6 Simon Revell, Manager of ... discuss how Web 2.0,social software can be leveraged to stimulate ...
Cached Biology Technology:Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 9Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 2Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 3Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 4Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 5Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 6Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 7Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 8Genomic Health Announces First Quarter 2008 Financial Results and Business Progress 9Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development 2Hershey Center for Applied Research Supports Acceleration of Scientific Research and Development 3
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... mind, it takes some fluorescent protein and a tiny microscope ... a technique for observing hundreds of neurons firing in the ... linked that activity to long-term information storage. The unprecedented work ... neurodegenerative diseases such as Alzheimer,s. The researchers first used ...
... Lab will host its sixth Geothermal Energy Utilization Conference ... Jon Wellinghoff, chairman of the Federal Energy Regulatory Commission, ... manager of the U.S. Department of Energy Geothermal Technologies ... The conference will advance the understanding of ...
... and frogs are about to take up residence in the ... and scientists want to learn more about the water-running lizard,s ... that means how it increases its locomotion efficiency by producing ... its recovery stroke. And these engineers are surprised at ...
Cached Biology News:Stanford researchers develop tool for reading the minds of mice 2SMU conference aims to spur development of geothermal production in oil and gas fields 2SMU conference aims to spur development of geothermal production in oil and gas fields 3Nature's phenomena might teach Virginia Tech engineers new tricks 2Nature's phenomena might teach Virginia Tech engineers new tricks 3
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... DS-L2 imaging controller is a successor of ... allows users to comfortably observe, record and ... features an 8.4 inch LCD (XGA) monitor ... Nikon cameras including the DS-Fi1 , DS-5Mc ...
... system for detection of very low level ... Equipped with an extreme sensitive camera to ... plants in tumor research, infectious disease research, ... NightOWL is the only imager with a ...
Biology Products: